DOCSLIB.ORG

Mouse Cfap298 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Cfap298 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Cfap298 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Cfap298 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Cfap298 gene (NCBI Reference Sequence: NM_026502.2 ; Ensembl: ENSMUSG00000022972 ) is located on Mouse chromosome 16. 7 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 7 (Transcript: ENSMUST00000023694). Exon 2~3 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Cfap298 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP24-100B13 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 2 starts from about 16.09% of the coding region. The knockout of Exon 2~3 will result in frameshift of the gene. The size of intron 1 for 5'-loxP site insertion: 3420 bp, and the size of intron 3 for 3'-loxP site insertion: 2407 bp. The size of effective cKO region: ~1746 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 7 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Cfap298 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. It may be difficult to construct this targeting vector. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(8246bp) | A(23.7% 1954) | C(26.18% 2159) | T(24.53% 2023) | G(25.59% 2110) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. Significant high GC-content regions are found. It may be difficult to construct this targeting vector. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr16 - 90931412 90934411 3000 browser details YourSeq 107 477 1040 3000 77.9% chr7 - 110291579 110291828 250 browser details YourSeq 100 469 608 3000 86.0% chr14 + 76370369 76370506 138 browser details YourSeq 89 1318 1753 3000 89.4% chr15 + 16463059 16463572 514 browser details YourSeq 88 718 1881 3000 94.0% chr18 - 38026820 38373404 346585 browser details YourSeq 84 468 584 3000 86.4% chr2 - 138964161 138964280 120 browser details YourSeq 84 476 584 3000 92.0% chr18 - 42458590 42458740 151 browser details YourSeq 83 521 609 3000 96.7% chr11 - 69725626 69725714 89 browser details YourSeq 80 830 1353 3000 90.0% chr17 + 15389102 15389685 584 browser details YourSeq 77 718 891 3000 88.2% chr9 - 94478028 94478202 175 browser details YourSeq 74 1138 1376 3000 90.3% chr10 + 76200830 76201103 274 browser details YourSeq 74 697 885 3000 90.2% chr1 + 125427229 125830354 403126 browser details YourSeq 71 718 843 3000 88.3% chr7 + 122899956 122900079 124 browser details YourSeq 71 718 891 3000 85.2% chr1 + 133938767 133938940 174 browser details YourSeq 70 718 892 3000 79.9% chr7 - 65247419 65247590 172 browser details YourSeq 68 697 880 3000 80.0% chrX - 11682428 11682610 183 browser details YourSeq 68 718 877 3000 88.9% chr18 - 14975098 14975256 159 browser details YourSeq 67 476 602 3000 86.1% chr15 - 101243278 101243403 126 browser details YourSeq 66 722 886 3000 86.6% chr14 - 62618820 62618983 164 browser details YourSeq 66 718 873 3000 86.6% chr7 + 117968819 117968972 154 Note: The 3000 bp section upstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr16 - 90926666 90929665 3000 browser details YourSeq 73 285 472 3000 91.3% chr19 + 36070064 36070267 204 browser details YourSeq 67 257 462 3000 87.7% chr13 + 47457078 47457523 446 browser details YourSeq 63 1461 1602 3000 89.9% chr15 - 77426310 77426471 162 browser details YourSeq 49 428 479 3000 98.1% chr1 - 165787383 165787681 299 browser details YourSeq 48 420 471 3000 98.1% chr12 + 30735110 30735416 307 browser details YourSeq 47 1462 1552 3000 94.5% chr16 - 4575204 4575308 105 browser details YourSeq 45 359 439 3000 78.8% chr18 - 10259013 10259074 62 browser details YourSeq 43 304 388 3000 74.6% chr11 + 99987835 99987907 73 browser details YourSeq 42 1558 1615 3000 83.0% chr12 + 41064064 41064117 54 browser details YourSeq 39 728 775 3000 93.5% chr11 + 95408730 95408785 56 browser details YourSeq 38 723 774 3000 93.1% chr13 + 56704263 56704320 58 browser details YourSeq 38 1466 1633 3000 93.1% chr11 + 88836518 88836686 169 browser details YourSeq 37 725 778 3000 86.1% chr14 - 24729941 24729992 52 browser details YourSeq 37 1576 1631 3000 76.8% chr1 + 59189406 59189454 49 browser details YourSeq 36 1580 1627 3000 83.0% chr1 + 132393487 132393533 47 browser details YourSeq 35 725 774 3000 94.8% chr11 - 120839889 120839939 51 browser details YourSeq 35 1558 1602 3000 82.1% chr12 + 84324000 84324040 41 browser details YourSeq 33 311 388 3000 76.4% chr11 - 88273950 88274016 67 browser details YourSeq 33 362 431 3000 90.3% chr13 + 18231426 18231534 109 Note: The 3000 bp section downstream of Exon 3 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Cfap298 cilia and flagella associate protien 298 [ Mus musculus (house mouse) ] Gene ID: 68001, updated on 26-Jun-2020 Gene summary Official Symbol Cfap298 provided by MGI Official Full Name cilia and flagella associate protien 298 provided by MGI Primary source MGI:MGI:1915251 See related Ensembl:ENSMUSG00000022972 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as 1110004E09Rik Expression Ubiquitous expression in testis adult (RPKM 38.1), CNS E11.5 (RPKM 13.4) and 28 other tissues See more Genomic context Location: 16; 16 C3.3 See Cfap298 in Genome Data Viewer Exon count: 7 Annotation release Status Assembly Chr Location 108.20200622 current GRCm38.p6 (GCF_000001635.26) 16 NC_000082.6 (90925811..90934849, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 16 NC_000082.5 (90926056..90935094, complement) Chromosome 16 - NC_000082.6 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 7 transcripts Gene: Cfap298 ENSMUSG00000022972 Description cilia and flagella associate protien 298 [Source:MGI Symbol;Acc:MGI:1915251] Gene Synonyms 1110004E09Rik Location Chromosome 16: 90,925,809-90,935,114 reverse strand. GRCm38:CM001009.2 About this gene This gene has 7 transcripts (splice variants), 268 orthologues and is a member of 1 Ensembl protein family. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Cfap298- ENSMUST00000023694.10 1430 290aa ENSMUSP00000023694.3 Protein coding CCDS28321 Q8BL95 TSL:1 201 GENCODE basic APPRIS P1 Cfap298- ENSMUST00000149833.7 597 198aa ENSMUSP00000123417.1 Protein coding - D3YZC4 CDS 3' 206 incomplete TSL:5 Cfap298- ENSMUST00000142340.1 560 150aa ENSMUSP00000120107.1 Protein coding - D3YUI6 CDS 3' 205 incomplete TSL:5 Cfap298- ENSMUST00000129345.7 489 156aa ENSMUSP00000122163.1 Protein coding - F7C0A6 CDS 5' 203 incomplete TSL:5 Cfap298- ENSMUST00000125519.7 1014 145aa ENSMUSP00000117691.1 Nonsense mediated - D6REH7 TSL:5 202 decay Cfap298- ENSMUST00000131583.1 374 No - Processed transcript - - TSL:3 204 protein Cfap298- ENSMUST00000231711.1 426 No - Retained intron - - - 207 protein Page 6 of 8 https://www.alphaknockout.com 29.31 kb Forward strand 90.92Mb 90.93Mb 90.94Mb Genes Gm49727-201 >TEC 4930534H18Rik-201 >bidirectional promoter lncRNA (Comprehensive set... Contigs < AC134560.5 Genes < Cfap298-201protein coding < Synj1-203protein coding (Comprehensive set... < Cfap298-203protein coding < Synj1-210protein coding < Cfap298-202nonsense mediated decay < Synj1-202protein coding < Cfap298-207retained intron < Synj1-208protein coding < Cfap298-206protein coding < Synj1-205processed transcript < Cfap298-205protein coding < Synj1-206protein coding < Cfap298-204processed transcript < Synj1-212protein coding < Synj1-204protein coding Regulatory Build 90.92Mb 90.93Mb 90.94Mb Reverse strand 29.31 kb Regulation Legend CTCF Open Chromatin Promoter Promoter Flank Gene Legend Protein Coding merged Ensembl/Havana Ensembl protein coding Non-Protein Coding Bidirectional promoter lncRNA processed transcript Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000023694 < Cfap298-201protein coding Reverse strand 9.31 kb ENSMUSP00000023... Low complexity (Seg) Pfam Cilia- and flagella-associated protein 298 PANTHER PTHR13238:SF4 Cilia- and flagella-associated protein 298 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend missense variant synonymous variant Scale bar 0 40 80 120 160 200 240 290 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 8 of 8.
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • ZMYND10 Functions in a Chaperone Relay During Axonemal Dynein
    RESEARCH ARTICLE ZMYND10 functions in a chaperone relay during axonemal dynein assembly Girish R Mali1†‡, Patricia L Yeyati1†, Seiya Mizuno2, Daniel O Dodd1, Peter A Tennant1, Margaret A Keighren1, Petra zur Lage3, Amelia Shoemark4, Amaya Garcia-Munoz5, Atsuko Shimada6, Hiroyuki Takeda6, Frank Edlich7,8, Satoru Takahashi2,9, Alex von Kreigsheim5,10, Andrew P Jarman3, Pleasantine Mill1* 1MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; 2Laboratory Animal Resource Centre, University of Tsukuba, Tsukuba, Japan; 3Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom; 4Division of Molecular and Clinical Medicine, University of Dundee, Dundee, United Kingdom; 5Systems Biology Ireland, University College Dublin, Dublin, Ireland; 6Department of Biological Sciences, University of Tokyo, Tokyo, Japan; 7Institute for Biochemistry and Molecular Biology, University of Freiburg, Freiburg, Germany; 8BIOSS, Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany; 9Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; 10Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom *For correspondence: [email protected] †These authors contributed Abstract Molecular chaperones promote the folding and macromolecular assembly of a diverse equally to this work set of ‘client’ proteins. How ubiquitous chaperone machineries direct their activities towards specific sets of substrates is unclear. Through the use of mouse genetics, imaging and quantitative Present address: ‡MRC Laboratory of Molecular Biology, proteomics we uncover that ZMYND10 is a novel co-chaperone that confers specificity for the Cambridge, United Kingdom FKBP8-HSP90 chaperone complex towards axonemal dynein clients required for cilia motility.
    [Show full text]
  • Test Catalogue August 2019
    Test Catalogue August 2019 www.centogene.com/catalogue Table of Contents CENTOGENE CLINICAL DIAGNOSTIC PRODUCTS AND SERVICES › Whole Exome Testing 4 › Whole Genome Testing 5 › Genome wide CNV Analysis 5 › Somatic Mutation Analyses 5 › Biomarker Testing, Biochemical Testing 6 › Prenatal Testing 7 › Additional Services 7 › Metabolic Diseases 9 - 21 › Neurological Diseases 23 - 47 › Ophthalmological Diseases 49 - 55 › Ear, Nose and Throat Diseases 57 - 61 › Bone, Skin and Immune Diseases 63 - 73 › Cardiological Diseases 75 - 79 › Vascular Diseases 81 - 82 › Liver, Kidney and Endocrinological Diseases 83 - 89 › Reproductive Genetics 91 › Haematological Diseases 93 - 96 › Malformation and/or Retardation Syndromes 97 - 107 › Oncogenetics 109 - 113 ® › CentoXome - Sequencing targeting exonic regions of ~20.000 genes Test Test name Description code CentoXome® Solo Medical interpretation/report of WES findings for index 50029 CentoXome® Solo - Variants Raw data; fastQ, BAM, Vcf files along with variant annotated file in xls format for index 50028 CentoXome® Solo - with CNV Medical interpretation/report of WES including CNV findings for index 50103 Medical interpretation/report of WES in index, package including genome wide analyses of structural/ CentoXome® Solo - with sWGS 50104 large CNVs through sWGS Medical interpretation/report of WES in index, package including genome wide analyses of structural/ CentoXome® Solo - with aCGH 750k 50122 large CNVs through 750k microarray Medical interpretation/report of WES in index, package including genome
    [Show full text]
  • Novel Gene Discovery in Primary Ciliary Dyskinesia
    Novel Gene Discovery in Primary Ciliary Dyskinesia Mahmoud Raafat Fassad Genetics and Genomic Medicine Programme Great Ormond Street Institute of Child Health University College London A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy University College London 1 Declaration I, Mahmoud Raafat Fassad, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Abstract Primary Ciliary Dyskinesia (PCD) is one of the ‘ciliopathies’, genetic disorders affecting either cilia structure or function. PCD is a rare recessive disease caused by defective motile cilia. Affected individuals manifest with neonatal respiratory distress, chronic wet cough, upper respiratory tract problems, progressive lung disease resulting in bronchiectasis, laterality problems including heart defects and adult infertility. Early diagnosis and management are essential for better respiratory disease prognosis. PCD is a highly genetically heterogeneous disorder with causal mutations identified in 36 genes that account for the disease in about 70% of PCD cases, suggesting that additional genes remain to be discovered. Targeted next generation sequencing was used for genetic screening of a cohort of patients with confirmed or suggestive PCD diagnosis. The use of multi-gene panel sequencing yielded a high diagnostic output (> 70%) with mutations identified in known PCD genes. Over half of these mutations were novel alleles, expanding the mutation spectrum in PCD genes. The inclusion of patients from various ethnic backgrounds revealed a striking impact of ethnicity on the composition of disease alleles uncovering a significant genetic stratification of PCD in different populations.
    [Show full text]
  • CFAP298 CRISPR/Cas9 KO Plasmid (M): Sc-426869
    SANTA CRUZ BIOTECHNOLOGY, INC. CFAP298 CRISPR/Cas9 KO Plasmid (m): sc-426869 BACKGROUND APPLICATIONS The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CFAP298 CRISPR/Cas9 KO Plasmid (m) is recommended for the disruption of CRISPR-associated protein (Cas9) system is an adaptive immune response gene expression in mouse cells. defense mechanism used by archea and bacteria for the degradation of foreign genetic material (4,6). This mechanism can be repurposed for other 20 nt non-coding RNA sequence: guides Cas9 functions, including genomic engineering for mammalian systems, such as to a specific target location in the genomic DNA gene knockout (KO) (1,2,3,5). CRISPR/Cas9 KO Plasmid products enable the U6 promoter: drives gRNA scaffold: helps Cas9 identification and cleavage of specific genes by utilizing guide RNA (gRNA) expression of gRNA bind to target DNA sequences derived from the Genome-scale CRISPR Knock-Out (GeCKO) v2 library developed in the Zhang Laboratory at the Broad Institute (3,5). Termination signal Green Fluorescent Protein: to visually REFERENCES verify transfection CRISPR/Cas9 Knockout Plasmid CBh (chicken β-Actin 1. Cong, L., et al. 2013. Multiplex genome engineering using CRISPR/Cas hybrid) promoter: drives systems. Science 339: 819-823. 2A peptide: expression of Cas9 allows production of both Cas9 and GFP from the 2. Mali, P., et al. 2013. RNA-guided human genome engineering via Cas9. same CBh promoter Science 339: 823-826. Nuclear localization signal 3. Ran, F.A., et al. 2013. Genome engineering using the CRISPR-Cas9 system. Nuclear localization signal SpCas9 ribonuclease Nat. Protoc. 8: 2281-2308.
    [Show full text]
  • Mapping Transmembrane Binding Partners for E-Cadherin Ectodomains
    SUPPLEMENTARY INFORMATION TITLE: Mapping transmembrane binding partners for E-cadherin ectodomains. AUTHORS: Omer Shafraz 1, Bin Xie 2, Soichiro Yamada 1, Sanjeevi Sivasankar 1, 2, * AFFILIATION: 1 Department of Biomedical Engineering, 2 Biophysics Graduate Group, University of California, Davis, CA 95616. *CORRESPONDING AUTHOR: Sanjeevi Sivasankar, Tel: (530)-754-0840, Email: [email protected] Figure S1: Western blots a. EC-BioID, WT and Ecad-KO cell lysates stained for Ecad and tubulin. b. HRP-streptavidin staining of biotinylated proteins eluted from streptavidin coated magnetic beads incubated with cell lysates of EC-BioID with (+) and without (-) exogenous biotin. c. C-BioID, WT and Ecad-KO cell lysates stained for Ecad and tubulin. d. HRP-streptavidin staining of biotinylated proteins eluted from streptavidin coated magnetic beads incubated with cell lysates of C-BioID with (+) and without (-) exogenous biotin. (+) Biotin (-) Biotin Sample 1 Sample 2 Sample 3 Sample 4 Sample 1 Sample 2 Sample 3 Sample 4 Percent Percent Percent Percent Percent Percent Percent Percent Gene ID Coverage Coverage Coverage Coverage Coverage Coverage Coverage Coverage CDH1 29.6 31.4 41.1 36.5 10.8 6.7 28.8 29.1 DSG2 26 14.6 45 37 0.8 1.9 1.6 18.7 CXADR 30.2 26.2 32.7 27.1 0.0 0.0 0.0 6.9 EFNB1 24.3 30.6 24 30.3 0.0 0.0 0.0 0.0 ITGA2 16.5 22.2 30.1 33.4 1.1 1.1 5.2 7.2 CDH3 21.8 9.7 20.6 25.3 1.3 1.3 0.0 0.0 ITGB1 11.8 16.7 23.9 20.3 0.0 2.9 8.5 5.8 DSC3 9.7 7.5 11.5 13.3 0.0 0.0 2.6 0.0 EPHA2 23.2 31.6 31.6 30.5 0.8 0.0 0.0 5.7 ITGB4 21.8 27.8 33.1 30.7 0.0 1.2 3.9 4.4 ITGB3 23.5 22.2 26.8 24.7 0.0 0.0 5.2 9.1 CDH6 22.8 18.1 28.6 24.3 0.0 0.0 0.0 9.1 CDH17 8.8 12.4 20.7 18.4 0.0 0.0 0.0 0.0 ITGB6 12.7 10.4 14 17.1 0.0 0.0 0.0 1.7 EPHB4 11.4 8.1 14.2 16.3 0.0 0.0 0.0 0.0 ITGB8 5 10 15 17.6 0.0 0.0 0.0 0.0 ITGB5 6.2 9.5 15.2 13.8 0.0 0.0 0.0 0.0 EPHB2 8.5 4.8 9.8 12.1 0.0 0.0 0.0 0.0 CDH24 5.9 7.2 8.3 9 0.0 0.0 0.0 0.0 Table S1: EC-BioID transmembrane protein hits.
    [Show full text]
  • Modelling the Developmental Spliceosomal Craniofacial Disorder
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.094029; this version posted May 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Modelling the developmental spliceosomal craniofacial disorder Burn -McKeown syndrome using induced pluripotent stem cells Short title: Modelling Burn -McKeown Syndrome using induced pluripotent stem cells Katherine A. Wood 1,2 , Charlie F. Rowlands 1,2 , Huw B. Thomas 1, Steven Woods 3, Julieta O’Flaherty 3, Sofia Dou zg ou 1,2 , Su san J. Kimbe r3, William G. Newman 1,2 *,Raymond T. O’Keefe 1* 1Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK 2Manchester Centre for Genomic Medicine , Manchester University NHS Foundation Trust , Manchester Academic Health Science Centre, Manc hester, UK 3Division of Cell Matrix Biology and Regenerative Medicine, School of Biology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK *To whom correspondence should be addressed. Email: [email protected] ; [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.094029; this version posted May 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
    [Show full text]
  • Protein List
    Protein Accession Protein Id Protein Name P11171 41 Protein 4.
    [Show full text]
  • Whole Exome Sequencing Gene Package Multiple Congenital Anomaly, Version 8.1, 31-1-2020
    Whole Exome Sequencing Gene package Multiple congenital anomaly, version 8.1, 31-1-2020 Technical information DNA was enriched using Agilent SureSelect DNA + SureSelect OneSeq 300kb CNV Backbone + Human All Exon V7 capture and paired-end sequenced on the Illumina platform (outsourced). The aim is to obtain 10 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate and non-unique reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA-MEM algorithm (reference: http://bio-bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 [Blood group, P1Pk system, p phenotype], 111400 NOR poly607922 146 100 100 99 AAAS Achalasia-addisonianism-alacrimia syndrome, 231550 605378 102 100 100 100
    [Show full text]
  • TEST CATALOGUE October 2020 ACHIEVING a POSITIVE CHANGE
    TEST CATALOGUE October 2020 ACHIEVING A POSITIVE CHANGE ... CENTOGENE IS DEDICATED TO TRANSFORMING THE SCIENCE OF GENETIC INFORMATION INTO SOLUTIONS AND HOPE FOR PATIENTS WITH RARE DISEASES AND THEIR FAMILIES. BOSTON We achieve this by: › Leveraging the world’s largest database in rare genetic disorders with genetic, proteomic, metabolomic, and clinical information – CentoMD® › Applying our knowledge derived from our global diagnostic testing services – addressing the worldwide heterogeneity in ethnicities › Guaranteeing the highest quality in our processes based on the highest level of accreditation OUR GLOBAL FOOTPRINT The outcome of growth and expansion at CENTOGENE is the inauguration of new locations. As a cosmopolitan company, we have a strong international footprint. ROSTOCK HAMBURG BERLIN DELHI FRANKFURT VIENNA DUBAI SOLID GROWTH IN JUST OVER A DECADE Metabolomic Oncogenetic Biomarkers MLPA >180 NGS panels platform testing CentoCard® qPCR Whole exome 2006 The logistic solution sequencing Diagnostics in neurogenetic diseases Non-invasive Carrier > 9,000 Whole genome prenatal testing screening different test sequencing 2016 (CentoNIPT®) (CentoScreen®) assays CentoMD® Proteomic Microarrays High throughput Transcriptomics The mutation platform genomic facility 2018 database iPSC program IPO Artificial Intelligence 2020+ initiative 2019 Providing world-class genetic testing and life-changing solutions for all rare disease patients 2019 WHAT DRIVES CENTOGENE Our goal: providing precise medical diagnosis of inherited diseases at the earliest possible moment; transforming medical expertise and analytical information into actionable results for physicians, patients, and pharmaceutical partners. Our commitment: life-long support for our patients and partners - driven by the continuous improvement of our diagnostic quality and therapeutic options for individual patients. Our work does not end by just delivering a medical diagnosis.
    [Show full text]
  • Emerging Genotype-Phenotype Relationships in Primary Ciliary Dyskinesia
    International Journal of Molecular Sciences Review Emerging Genotype-Phenotype Relationships in Primary Ciliary Dyskinesia Steven K Brennan 1,* , Thomas W Ferkol 1 and Stephanie D Davis 2 1 Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Campus Box 8116, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA; [email protected] 2 Department of Pediatrics, University of North Carolina School of Medicine, 101 Manning Drive, Chapel Hill, NC 27514, USA; [email protected] * Correspondence: [email protected] Abstract: Primary ciliary dyskinesia (PCD) is a rare inherited condition affecting motile cilia and leading to organ laterality defects, recurrent sino-pulmonary infections, bronchiectasis, and severe lung disease. Research over the past twenty years has revealed variability in clinical presentations, ranging from mild to more severe phenotypes. Genotype and phenotype relationships have emerged. The increasing availability of genetic panels for PCD continue to redefine these genotype-phenotype relationships and reveal milder forms of disease that had previously gone unrecognized. Keywords: primary ciliary dyskinesia; molecular genetics; genotype-phenotype association Citation: Brennan, S.K.; Ferkol, T.W.; 1. Introduction Davis, S.D. Emerging Genotype- Phenotype Relationships in Primary Motile ciliopathies are a group of disorders where motile cilia lining embryonic cells, Ciliary Dyskinesia. Int. J. Mol. Sci. airways, sinus and inner ear cavities, and ventricles in the brain are dysfunctional. The 2021, 22, 8272. https://doi.org/ primary function of these hair-like projections is to facilitate the movement of fluid (i.e., 10.3390/ijms22158272 mucus that lines the airways, cerebrospinal fluid) within various body cavities to be either recirculated or expelled [1].
    [Show full text]
  • Computational Prediction of the Pathogenic Status of Cancer-Specific Somatic Variants
    Computational prediction of the pathogenic status of cancer-specific somatic variants By: Nikta Feizi A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba In partial fulfillment of the requirements of the degree of MASTER OF SCIENCE Department of Biochemistry and Medical Genetics University of Manitoba Winnipeg, Manitoba, Canada Copyright © 2019 by Nikta Feizi 1 Abstract The ever-increasing shift in cancer genetic testing is accompanied by a demand for interpretation of the results. In-silico interpretation approaches are shown to be promising in increasing the clinical utilization of genetic tests by classifying variants into well-defined pathogenic and non-pathogenic clinical groups. Current prediction tools are mostly trained based on the characteristics of germ-line variants and utilized for classifying both gremline and somatic variants, which may result in biased predictions in the event of classifying somatic variants. Considering the critical role of somatic variants in cancer occurrence and progression establishing cancer specific prediction tools which are designed solely based on the characteristics of somatic variants is of high importance. To this aim, we established a gold standard dataset exclusively for cancer somatic single nucleotide variants (SNVs) collected from the catalogue of somatic mutations in cancer (COSMIC). To label the pathogenic (positive) variants we introduced a bi-dimensional recurrence score spanning both the frequency of a given mutation across a dataset and the number of cancer types the mutation affects. To label the non-pathogenic (negative) variants we collected the somatic SNVs with the minor allele frequency of equal or greater than 1% in at least one of 26 populations from 1000 Genomes project that are also defined in COSMIC.
    [Show full text]